Bioequivalence of antiepileptic drugs: How close is close enough?
- 9 June 2009
- journal article
- review article
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 9 (4) , 333-337
Abstract
During the past few years, the use and substitution of generic antiepileptic drug products has been increasing both in the United States as well as globally. Although these less expensive products may represent an important alternative for many patients, there may be reasons for concern. Despite well-controlled regulatory studies, concerns persist regarding potential therapeutic inequivalence in some patients with epilepsy. These concerns have prompted some in the US neurology community as well as patient advocacy groups to question the current regulatory requirements for both establishing bioequivalence as well as product substitution. In addition, recent data have questioned the actual cost savings associated with generic substitution in this unique patient population. This article reviews current regulatory requirements and pharmacokinetic, biopharmaceutical, and clinical outcome issues that clinicians, pharmacists, and policymakers should consider regarding generic substitution of these complicated agents.Keywords
This publication has 27 references indexed in Scilit:
- Case‐control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changesEpilepsia, 2009
- Debate: Substitution of generic drugs in epilepsy: Is there cause for concern?Epilepsia, 2008
- Clinical consequences of generic substitution of lamotrigine for patients with epilepsyNeurology, 2008
- Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian settingCurrent Medical Research and Opinion, 2008
- Generic Products of Antiepileptic Drugs (AEDs): Is It an Issue?Epilepsia, 2007
- The Economic Consequences of Generic Substitution for Antiepileptic Drugs in a Public Payer Setting: The Case of LamotrigineDisease Management, 2007
- What’s the problem with generic antiepileptic drugs?Neurology, 2007
- Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsyNeurology, 2007
- Compulsory Generic Switching of Antiepileptic Drugs: High Switchback Rates to Branded Compounds Compared with Other Drug ClassesEpilepsia, 2007
- Drug absorption in the elderly: Biopharmaceutical considerations for the antiepileptic drugsEpilepsy Research, 2006